| Dr Ishmael A Jaiyesimi, DO | |
|
3577 W 13 Mile Rd, Suite 404, Royal Oak, MI 48073-6710 | |
| (248) 551-6991 | |
| (248) 551-6910 |
| Full Name | Dr Ishmael A Jaiyesimi |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 38 Years |
| Location | 3577 W 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538128178 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 5101009654 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Beaumont Hospital - Farmington Hills | Farmington hills, MI | Hospital |
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Beaumont Hospital - Grosse Pointe | Grosse pointe, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beaumont Medical Group- Specialty Services | 7214299866 | 787 |
| Michigan Healthcare Professionals Pc | 0345413258 | 448 |
News Archive
A recent study led by scientists at the University of South Carolina's Arnold School of Public Health has shown that adjusting GI tract viruses by repurposing existing FDA-approved antiviral drugs offers a route for effective treatment for Gulf War Illness and its myriad of symptoms.
Pall Corporation (NYSE:PLL) today reported financial results for the fourth quarter and fiscal year ended July 31, 2009. Sales and net earnings for the year were $2.3 billion and $195.6 million, respectively. Diluted earnings per share (EPS) were $1.64, compared to $1.76 a year earlier. Pro forma EPS were $1.77 versus last year's $1.97.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
Almost everyone knows how it feels to remember things for decades on end – and also how it feels to forget where you left your car keys. The answer to this strange paradox could be simple, according to a new study from Caltech. The researchers found that that the brain recruits a higher number of neurons which fire impulses in a synchronized manner to form and store strong memories over long periods.
› Verified 8 days ago
| Entity Name | Cancer Care Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750431102 PECOS PAC ID: 1557337102 Enrollment ID: O20040907000219 |
News Archive
A recent study led by scientists at the University of South Carolina's Arnold School of Public Health has shown that adjusting GI tract viruses by repurposing existing FDA-approved antiviral drugs offers a route for effective treatment for Gulf War Illness and its myriad of symptoms.
Pall Corporation (NYSE:PLL) today reported financial results for the fourth quarter and fiscal year ended July 31, 2009. Sales and net earnings for the year were $2.3 billion and $195.6 million, respectively. Diluted earnings per share (EPS) were $1.64, compared to $1.76 a year earlier. Pro forma EPS were $1.77 versus last year's $1.97.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
Almost everyone knows how it feels to remember things for decades on end – and also how it feels to forget where you left your car keys. The answer to this strange paradox could be simple, according to a new study from Caltech. The researchers found that that the brain recruits a higher number of neurons which fire impulses in a synchronized manner to form and store strong memories over long periods.
› Verified 8 days ago
| Entity Name | Michigan Healthcare Professionals Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295023547 PECOS PAC ID: 0345413258 Enrollment ID: O20111109000027 |
News Archive
A recent study led by scientists at the University of South Carolina's Arnold School of Public Health has shown that adjusting GI tract viruses by repurposing existing FDA-approved antiviral drugs offers a route for effective treatment for Gulf War Illness and its myriad of symptoms.
Pall Corporation (NYSE:PLL) today reported financial results for the fourth quarter and fiscal year ended July 31, 2009. Sales and net earnings for the year were $2.3 billion and $195.6 million, respectively. Diluted earnings per share (EPS) were $1.64, compared to $1.76 a year earlier. Pro forma EPS were $1.77 versus last year's $1.97.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
Almost everyone knows how it feels to remember things for decades on end – and also how it feels to forget where you left your car keys. The answer to this strange paradox could be simple, according to a new study from Caltech. The researchers found that that the brain recruits a higher number of neurons which fire impulses in a synchronized manner to form and store strong memories over long periods.
› Verified 8 days ago
| Entity Name | Beaumont Medical Group- Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578072906 PECOS PAC ID: 7214299866 Enrollment ID: O20180320002549 |
News Archive
A recent study led by scientists at the University of South Carolina's Arnold School of Public Health has shown that adjusting GI tract viruses by repurposing existing FDA-approved antiviral drugs offers a route for effective treatment for Gulf War Illness and its myriad of symptoms.
Pall Corporation (NYSE:PLL) today reported financial results for the fourth quarter and fiscal year ended July 31, 2009. Sales and net earnings for the year were $2.3 billion and $195.6 million, respectively. Diluted earnings per share (EPS) were $1.64, compared to $1.76 a year earlier. Pro forma EPS were $1.77 versus last year's $1.97.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
Almost everyone knows how it feels to remember things for decades on end – and also how it feels to forget where you left your car keys. The answer to this strange paradox could be simple, according to a new study from Caltech. The researchers found that that the brain recruits a higher number of neurons which fire impulses in a synchronized manner to form and store strong memories over long periods.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ishmael A Jaiyesimi, DO 3577 W 13 Mile Rd, Suite 404, Royal Oak, MI 48073-6710 Ph: (248) 551-6991 | Dr Ishmael A Jaiyesimi, DO 3577 W 13 Mile Rd, Suite 404, Royal Oak, MI 48073-6710 Ph: (248) 551-6991 |
News Archive
A recent study led by scientists at the University of South Carolina's Arnold School of Public Health has shown that adjusting GI tract viruses by repurposing existing FDA-approved antiviral drugs offers a route for effective treatment for Gulf War Illness and its myriad of symptoms.
Pall Corporation (NYSE:PLL) today reported financial results for the fourth quarter and fiscal year ended July 31, 2009. Sales and net earnings for the year were $2.3 billion and $195.6 million, respectively. Diluted earnings per share (EPS) were $1.64, compared to $1.76 a year earlier. Pro forma EPS were $1.77 versus last year's $1.97.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
Almost everyone knows how it feels to remember things for decades on end – and also how it feels to forget where you left your car keys. The answer to this strange paradox could be simple, according to a new study from Caltech. The researchers found that that the brain recruits a higher number of neurons which fire impulses in a synchronized manner to form and store strong memories over long periods.
› Verified 8 days ago
Nicole Marijanovich, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-7999 Fax: 248-898-0580 | |
Vinayata Manuballa Kareti, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 661-948-0803 | |
Filip Ionescu, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-551-3000 | |
Christopher Carpenter, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3535 W 13 Mile Rd Ste 605, Royal Oak, MI 48073 Phone: 248-551-0495 | |
Dr. Matthew Burns Cotant, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3577 W 13 Mile Rd, Suite 404, Royal Oak, MI 48073 Phone: 248-551-6900 Fax: 248-551-6909 | |
Geoffrey Prysak, MD, MPH Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-7999 | |
Taylor Schoenheit, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-6509 |